142 results on '"Jordi Navarro"'
Search Results
2. Syndemic conditions and quality of life in the PISCIS Cohort of people living with HIV in Catalonia and the Balearic Islands: a cross sectional study
- Author
-
Jocelyn Mesías-Gazmuri, Cinta Folch, Jorge Palacio-Vieira, Andreu Bruguera, Laia Egea-Cortés, Carlos G. Forero, Juan Hernández, José M. Miró, Jordi Navarro, Melchor Riera, Joaquim Peraire, Lucía Alonso-García, Yesika Díaz, Jordi Casabona, and Juliana Reyes-Urueña
- Subjects
People living with HIV, health-related quality of life ,HIV ,Syndemic ,Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
Abstract Background People living with HIV (PLWH) face structural and psychosocial factors that affect health-related quality of life (HRQoL). We aimed to evaluate how syndemic conditions affected HRQoL in PLWH. Methods A cross-sectional survey was conducted among 861 PLWH, to determine whether syndemic conditions (monthly income; sexual satisfaction; depressive symptoms; social role satisfaction; social isolation; cognitive function; nicotine dependence; perception of stigma) have an effect on HRQoL. A linear regression model and measures of Additive Interaction (AI) were used to determine the effects of syndemic conditions on HRQoL, controlling for other risk factors. Results Overall, the most frequently observed were stigma perception (56.9%), poor cognitive function (50.6%) and the perception of social isolation (51.6%). The presence of depressive symptoms was the risk factor most associated with worse Physical Health (PH) (B 3.93, 2.71–5.15) and Mental Health (MH) (B 5.08, 3.81–6.34) in linear regression model. Specifically, an interaction was observed between poor cognitive function and poor satisfaction with social role on worse PH and MH (AI 2.08, 0.14–4.02; AI 2.69, 0.15–5.22, respectively); and low income and perception of stigma (AI 2.98, 0.26–5.71), low income and perception of social isolation (AI 2.79, 0.27–5.32), and low income and poor satisfaction with social role (AI 3.45, 0.99–5.91) on MH. Conclusion These findings provide evidence that syndemic factors impact HRQoL. HIV prevention programs should screen and address co-occurring health problems to improve patient-centered health care and outcomes.
- Published
- 2023
- Full Text
- View/download PDF
3. Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS eventsResearch in context
- Author
-
Javier Martínez-Sanz, Jorge Díaz-Álvarez, Marta Rosas, Raquel Ron, José Antonio Iribarren, Enrique Bernal, Félix Gutiérrez, Andrés Ruiz Sancho, Noemi Cabello, Julián Olalla, Santiago Moreno, Sergio Serrano-Villar, Inma Jarrín, David Dalmau, M. Luisa Navarro, M. Isabel González, Federico Garcia, Eva Poveda, Jose Antonio Iribarren, Rafael Rubio, Francesc Vidal, Juan Berenguer, Juan González, M. Ángeles Muñoz-Fernández, Inmaculada Jarrín, Cristina Moreno, Marta Rava, Rebeca Izquierdo, Elba Mauleón, Joaquín Portilla, Irene Portilla, Esperanza Merino, Gema García, Iván Agea, José Sánchez-Payá, Juan Carlos Rodríguez, Livia Giner, Sergio Reus, Vicente Boix, Diego Torrus, Verónica Pérez, Julia Portilla, Juan Luís Gómez, Jehovana Hernández, Ana López Lirola, Dácil García, Felicitas Díaz-Flores, M. Mar Alonso, Ricardo Pelazas, M. Remedios Alemán, Víctor Asensi, María Eugenia Rivas Carmenado, Tomás Suarez-Zarracina, Federico Pulido, Otilia Bisbal, M. Asunción Hernando, David Rial, María de Lagarde, Octavio Arce, Adriana Pinto, Laura Bermejo, Mireia Santacreu, Roser Navarro, Candela Gonzalez, M. José Aramburu, Xabier Camino, Miguel Ángel von Wichmann, Miguel Ángel Goenaga, M. Jesús Bustinduy, Harkaitz Azkune, Maialen Ibarguren, Xabier Kortajarena, Ignacio Álvarez-Rodriguez, Leire Gil, Lourdes Martínez, Catalina Robledano, Mar Masiá, Sergio Padilla, Araceli Adsuar, Rafael Pascual, Marta Fernández, Antonio Galiana, José Alberto García, Xavier Barber, Vanessa Agullo, Javier Garcia Abellán, Reyes Pascual, Guillermo Telenti, Lucia Guillén, Ángela Botella, Roberto Muga, Arantza Sanvisens, Daniel Fuster, Isabel Gutierrez, Juan Carlos López, Margarita Ramírez, Belén Padilla, Paloma Gijón, Teresa Aldamiz-Echevarría, Francisco Tejerina, Cristina Diez, Leire Pérez, Chiara Fanciulli, Saray Corral, Anna Martí, Joaquín Peraire, Consuelo Viladés, Montserrat Vargas, Montserrat Olona, Anna Rull, Verónica Alba, Elena Yeregui, Jenifer Masip, Graciano García-Pardo, Frederic Gómez Bertomeu, Sonia Espineira, Marta Montero, Sandra Cuéllar, Marino Blanes, María Tasias, Eva Calabuig, Miguel Salavert, Juan Fernández, Inmaculada Segarra, Juan González-García, Ana Delgado, Francisco Arnalich, José Ramón Arribas, Jose Ignacio Bernardino, Juan Miguel Castro, Luis Escosa, Pedro Herranz, Victor Hontañón, Silvia García-Bujalance, Milagros García, Alicia González-Baeza, M. Luz Martín-Carbonero, Mario Mayoral, M. Jose Mellado, Rafael Esteban, Rocío Montejano, M. Luisa Montes, Victoria Moreno, Ignacio Pérez-Valero, Berta Rodés, Guadalupe Rúa, Talía Sainz, Elena Sendagorta, Eulalia Valencia, Carmen Busca, Joanna Cano, Julen Cardiñanos, Rosa de Miguel, Jose Ramón Blanco, Laura Pérez-Martínez, José Antonio Oteo, Valvanera Ibarra, Luis Metola, Mercedes Sanz, Piedad Arazo, Gloria Sampériz, Marina Martinez, Angels Jaén, Montse Sanmartí, Mireia Cairó, Javier Martinez-Lacasa, Pablo Velli, Roser Font, Mariona Xercavins, Noemí Alonso, Francesco Aiello, María Rivero, Beatriz Piérola, Maider Goikoetxea, María Gracia, Carlos Ibero, Estela Moreno, Jesús Repáraz, Gemma Navarro, Manel Cervantes Garcia, Sonia Calzado Isbert, Marta Navarro Vilasaro, Belen Lopez Garcia, Ignacio de los Santos, Alejandro de los Santos, Jesús Sanz, Lucio García-Fraile, Enrique Martín, Ildefonso Sánchez-Cerrillo, Marta Calvet, Ana Barrios, Azucena Bautista, Carmen Sáez, Marianela Ciudad, Ángela Gutiérrez, Santos del Campo, José Luis Casado, Fernando Dronda, Ana Moreno, M. Jesús Pérez, Sergio Serrano, Ma Jesús Vivancos, Alejandro Vallejo, Matilde Sanchez, Jose Antonio Pérez-Molina, José Manuel Hermida, Antonia Alcaraz, Joaquín Bravo, Ángeles Muñoz, Cristina Tomás, Mónica Martínez, M. Carmen Villalba, Federico García, Clara Martínez, José Hernández, Leopoldo Muñoz Medina, Marta Álvarez, Natalia Chueca, David Vinuesa, Adolfo de Salazar, Ana Fuentes, Emilio Guirao, Laura Viñuela, Andrés Ruiz-Sancho, Francisco Anguita, Jorge Del Romero, Montserrat Raposo, Carmen Rodríguez, Teresa Puerta, Juan Carlos Carrió, Mar Vera, Juan Ballesteros, Oskar Ayerdi, Begoña Baza, Eva Orviz, Antonio Antela, Elena Losada, Melchor Riera, María Peñaranda, M. Angels Ribas, Antoni A. Campins, Mercedes Garcia-Gazalla, Francisco J. Fanjul, Javier Murillas, Francisco Homar, Helem H. Vilchez, Luisa Martin, Antoni Payeras, Jesús Santos, María López, Crisitina Gómez, Isabel Viciana, Rosario Palacios, Luis Fernando López-Cortés, Nuria Espinosa, Cristina Roca, Silvia Llaves, Juan Manuel Tiraboschi, Arkaitz Imaz, Ana Karina Silva, María Saumoy, Sofía Catalina Scévola, Adrián Curran, Vicenç Falcó, Jordi Navarro, Joaquin Burgos, Paula Suanzes, Jorge García, Vicente Descalzo, Patricia Álvarez, Bibiana Planas, Marta Sanchiz, Lucía Rodríguez, M José Sánchez, Javier Pérez, Alfonso del Arco, Javier de la Torre, José Luis Prada, Onofre Juan Martínez, Lorena Martinez, Francisco Jesús Vera, Josefina García, Begoña Alcaraz, Antonio Jesús Sánchez Guirao, Alvaro Mena, Angeles Castro, Berta Pernas, Pilar Vázquez, Soledad López, Sofía Ibarra, Guillermo García, Josu Mirena, Oscar Luis Ferrero, Josefina López, M. Mar Cámara, Mireia de la Peña, Miriam Lopez, Iñigo Lopez, Itxaso Lombide, Victor Polo, Joana de Miguel, Carlos Galera, Marian Fernández, Helena Albendin, Antonia Castillo, Asunción Iborra, Antonio Moreno, M. Angustias Merlos, Asunción Vidal, Concha Amador, Francisco Pasquau, Concepcion Gil, Jose Tomás Algado, Inés Suarez-García, Eduardo Malmierca, Patricia González-Ruano, M. Pilar Ruiz, José Francisco Pascual, Elena Sáez, Luz Balsalobre, M. Villa López, Mohamed Omar, Carmen Herrero, M. Amparo Gómez, Miguel Alberto de Zarraga, Desiré Pérez, Vicente Estrada, Nieves Sanz, Noemí Cabello, Jorge Vergas García, Maria Jose Núñez, Iñigo Sagastagoitia, Miguel Górgolas, Alfonso Cabello, Beatriz Álvarez, Laura Prieto, Irene Carrillo, José Sanz, Alberto Arranz, Cristina Hernández, María Novella, M. José Galindo, Ana Ferrer, Antonio Rivero Román, Inma Ruíz, Antonio Rivero Juárez, Pedro López, Isabel Machuca, Mario Frias, Ángela Camacho, Ignacio Pérez, Diana Corona, Miguel Cervero, Rafael Torres, Juan Antonio Pineda, Pilar Rincón, Juan Macías, Luis Miguel Real, Anais Corma, Alejandro Gonzalez-Serna, Alexandre Pérez, Luis Morano, Celia Miralles, Antonio Ocampo, Guillermo Pousada, Lucía Patiño, Carlos Dueñas, Sara Gutiérrez, Elena Tapia, Cristina Novoa, Xjoylin Egües, and Pablo Telleria
- Subjects
HIV ,Non-AIDS events ,Neoplasia ,Cardiovascular event ,CD4/CD8 ratio ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: While a low CD4/CD8 ratio during HIV treatment correlates with immunosenescence, its value in identifying patients at an increased risk for clinical events remains unclear. Methods: We analyzed data from the CoRIS cohort to determine whether CD4 count, CD8 count, and CD4/CD8 ratio at year two of antiretroviral therapy (ART) could predict the risk of serious non-AIDS events (SNAEs) during the next five years. These included major adverse cardiovascular events, non-AIDS-defining malignancies, and non-accidental deaths. We used pooled logistic regression with inverse probability weighting to estimate the survival curves and cumulative risk of clinical events. Findings: The study included 4625 participants, 83% male, of whom 200 (4.3%) experienced an SNAE during the follow-up period. A CD4/CD8 ratio
- Published
- 2023
- Full Text
- View/download PDF
4. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
- Author
-
José Ramón Santos, Maria Casadellà, Marc Noguera-Julian, Rafael Micán-Rivera, Pere Domingo, Antonio Antela, Joaquin Portilla, Jesús Sanz, Marta Montero-Alonso, Jordi Navarro, Mar Masiá, Nieves Valcarce-Pardeiro, Antonio Ocampo, Laura Pérez-Martínez, Coral García-Vallecillos, María Jesús Vivancos, Arkaitz Imaz, José Antonio Iribarren, José Hernández-Quero, Judit Villar-García, Pilar Barrufet, Roger Paredes, INSTINCT study group, Mariona Perera, Anna Chamorro, Cristina Miranda, Nástor Sánchez, Anna Garcı́á, Núria Pérez, Juan González Garcı́á, María del Mar Gutiérrez, María Gracia Mateo, Elena Losada, Sergio Reus, Vicente Boix, Diego Torrús, Esperanza Merino, Angela Gutiérrez Liarte, Adrià Curran, Félix Gutiérrez, Anna Mariño Callejo, Alvarez Diaz Hortensia, Antonio Ocampo Hermida, Celia Miralles, Laura Labajo Leal, Guillermo Pousada, José Ramon Blanco, José Antonio Oteo, Ibarra Valvanera, Mercedes Sanz, Luis Metola, Juan Pascua, Daniel Podzamczer, Camila Piatti, Maialen Ibarguren, Laia Arbones, Marta Ruiz, Sara Cervanntes, Helena Pera, Jessica Toro, Nuria Perez-Alvarez, and Anna Garcia
- Subjects
HIV ,integrase strand transfer inhibitors (INSTI) ,real-world study ,raltegravir ,elvitegravir ,dolutegravir ,Microbiology ,QR1-502 - Abstract
IntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, these drugs are not always available. An analysis of the experience with the use of INSTIs in unselected adults living with HIV may be of help to make therapeutic decisions when second-generation INSTIs are not available. This study aimed to evaluate the real-life effectiveness and safety of dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), and raltegravir (RAL) in a large Spanish cohort of HIV-1-infected patients.MethodsReal-world study of adults living with HIV who initiated integrase INSTIs DTG, EVG/c, and RAL-based regimens in three settings (ART-naïve patients, ART-switching, and ART-salvage patients). The primary endpoint was the median time to treatment discontinuation after INSTI-based regimen initiation. Proportion of patients experiencing virological failure (VF) (defined as two consecutive viral loads (VL) ≥200 copies/mL at 24 weeks or as a single determination of VL ≥1,000 copies/mL while receiving DTG, EVG/c or RAL, and at least 3 months after INSTI initiation) and time to VF were also evaluated.ResultsVirological effectiveness of EVG/c- and RAL-based regimens was similar to that of DTG when given as first-line and salvage therapy. Treatment switching for reasons other than virological failure was more frequent in subjects receiving EVG/c and, in particular, RAL. Naïve patients with CD4+ nadir
- Published
- 2023
- Full Text
- View/download PDF
5. Treatment of Aneurysmal Bone Cyst with Endoscopic Resection and Bone Allograft with Platelet-Rich Plasma: A Case Report
- Author
-
Alfred Ferré-Aniorte, Eduard Alentorn-Geli, Xavier Cuscó, David Barastegui, Roberto Seijas, Pedro Álvarez-Díaz, Jordi Navarro, Patricia Laiz, and Ramón Cugat
- Subjects
aneurysmal bone cyst ,platelet-rich plasma ,calcaneus ,Surgery ,RD1-811 - Abstract
An aneurysmal bone cyst (ABC) is a rare bone tumor usually observed in long bones. The surgical treatment of this pathology is often related to high recurrence rates, so novel biological techniques can help to enhance tissue regeneration and bone consolidation. We present a case of a patient with ABC of the calcaneus treated with an endoscopic resection followed by grafting with an autologous-based matrix composed of allograft bone chips and autologous platelet-rich plasma (PRP) in semisolid and liquid states. Patient demonstrated excellent defect filling in both magnetic resonance imaging and radiologic exams and returned to pre-injury activity with no recurrence at 2 years follow-up. Endoscopic curettage together with allograft bone and autologous PRP is effective in treating ABC patients and could be a good adjuvant treatment to prevent reinjury and enhance consolidation.
- Published
- 2023
- Full Text
- View/download PDF
6. Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa
- Author
-
Ramiro Manzano‐Nunez, Jesús Rivera‐Esteban, Jordi Navarro, Juan Bañares, Elena Sena, Jörn M. Schattenberg, Jeffrey V. Lazarus, Adria Curran, and Juan M. Pericàs
- Subjects
NAFLD ,MAFLD ,liver fibrosis ,HIV ,people living with HIV ,HIV epidemiology ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Introduction Non‐alcoholic fatty liver disease (NAFLD) has become a significant concern among people living with HIV (PLHIV), albeit its burden remains unclear. The primary objective of this systematic review (SR) and meta‐analysis (MA) was to estimate the prevalence of NAFLD and significant fibrosis in PLHIV. The secondary objective was to determine the risk factors for NAFLD among PLHIV. Methods We searched MEDLINE and Scopus from inception to 30 December 2022 for peer‐reviewed studies that included PLHIV and reported the prevalence of NAFLD. MA of proportions was used to estimate the pooled prevalence of NAFLD and significant fibrosis. MA of pre‐calculated effect estimates examined risk factors for NAFLD in PLHIV. Results We included 24 articles published between 2009 and 2022, encompassing 6326 PLHIV. The pooled prevalence of NAFLD was 38% (95% CI: 31–45%) with high heterogeneity (I2 = 96.3%). The pooled prevalence of significant fibrosis was 13% (95% CI: 8–18%) with high heterogeneity (I2 = 92.09%). Subgroup analyses showed a NAFLD prevalence of 40% (95% CI: 24–57%) in the United States, 33% (95% CI: 31–36) in Asia, 42% (95% CI: 24–61%) in Europe and 33% (95% CI: 29–37) in South America. When stratifying by income level, NAFLD was 39% (95% CI: 31–48) prevalent in PLHIV from high‐income economies and 34% in both upper‐middle‐income (95% CI: 31–37%) and lower‐middle‐income economies (95% CI: 28–41%). Higher body mass index (BMI) (OR = 1.32, 95% CI: 1.13–1.55; I2 = 89.9%), increasing triglycerides (OR = 1.48, 95% CI: 1.22–2.79; I2 = 27.2%) and dyslipidaemia (OR = 1.89, 95% CI: 1.32–2.71; I2 = 15.5%) were all associated with higher risk‐adjusted odds of NAFLD in PLHIV. Discussion The burden of NAFLD and significant fibrosis in PLHIV is significant. Therefore, targeted efforts to screen and diagnose NAFLD in this population are needed. Health services for PLHIV could include ways to target NAFLD risk factors, screen for liver disease and implement interventions to treat those with significant fibrosis or more advanced stages of liver disease. Taking no action to address NAFLD in PLHIV should not be an option. Conclusions This SR and MA found a 38% NAFLD and 13% significant fibrosis prevalence in PLHIV. Increasing triglyceride levels, higher BMI values and dyslipidaemia were associated with higher risk‐adjusted odds of NAFLD among PLHIV.
- Published
- 2023
- Full Text
- View/download PDF
7. Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
- Author
-
Brad Rovin, Bethany Wolf, Haikady N Nagaraja, Ana Malvar, Jordi Navarro, Valeria Alberton, Bruno Lococo, Joaquín Martinez, Maria Lourenco, Lucrecia Burna, Celeste Besso, and Aastha Khatiwada
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Abstract
Objective This study investigated changes in kidney histology over time in patients with lupus nephritis (LN) undergoing immunosuppressive treatment.Methods Patients with proliferative±membranous LN were studied. After a diagnostic kidney biopsy (Bx1), patients had protocol biopsy 2 (Bx2) at 9 (6–15) months and protocol biopsy 3 (Bx3) at 42 (28–67) months. Kidney histological activity and chronicity indices (AI, CI) were measured.Results AI declined in a biphasic fashion, falling rapidly between Bx1 and Bx2 and then more slowly between Bx2 and Bx3. Patients were divided into those who achieved histological remission, defined as an AI=0 at Bx3 (group 1), and those with persistent histological activity (AI >0) at Bx3 (group 2). The early decline in AI was 1.6 times greater (95% CI 1.30, 1.91) in group 1 than group 2 (p=0.01). Between Bx2 and Bx3, the AI decline was 2.19-fold greater (95% CI 2.09, 2.29) in group 1 versus group 2 (p=7.34×10−5). Individual histological components of the AI resolved at different rates. Inflammatory lesions like glomerular crescents, karyorrhexis and necrosis mostly resolved by Bx2, whereas endocapillary hypercellularity, subendothelial hyaline deposits and interstitial inflammation resolved slowly, accounting for residual histological activity at biopsy 3 in group 2. In contrast, CI increased rapidly, by 0.15 units/month between Bx1 and Bx2, then plateaued. There were no differences in the rate of accumulation of chronic damage between group 1 and group 2. The increase in CI was significantly related to the severity of glomerular crescents (p=0.044), subendothelial hyaline deposits (p=0.002) and interstitial inflammation (p=0.015) at Bx1.Conclusions LN histological activity takes months to years to resolve, providing a rationale for the need of long-term, well-tolerated maintenance immunosuppression. Despite responding, LN kidneys accrue chronic damage early during treatment. This finding provides an explanation for the association of chronic progressive kidney disease with recurrent episodes of LN.
- Published
- 2023
- Full Text
- View/download PDF
8. Peripheral and lung resident memory T cell responses against SARS-CoV-2
- Author
-
Judith Grau-Expósito, Nerea Sánchez-Gaona, Núria Massana, Marina Suppi, Antonio Astorga-Gamaza, David Perea, Joel Rosado, Anna Falcó, Cristina Kirkegaard, Ariadna Torrella, Bibiana Planas, Jordi Navarro, Paula Suanzes, Daniel Álvarez-Sierra, Alfonso Ayora, Irene Sansano, Juliana Esperalba, Cristina Andrés, Andrés Antón, Santiago Ramón y Cajal, Benito Almirante, Ricardo Pujol-Borrell, Vicenç Falcó, Joaquín Burgos, María J. Buzón, and Meritxell Genescà
- Subjects
Science - Abstract
Lung resident memory T (TRM) cells are important for protection from viral infection in the lungs. Here the authors use paired lung biopsy material and blood to characterize T cell responses in patients with COVID-19 over time and find persistence of antiviral lung TRM cells that might be important to limit reinfection.
- Published
- 2021
- Full Text
- View/download PDF
9. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
- Author
-
Óscar Brochado, Isidoro Martínez, Juan Berenguer, Luz Medrano, Juan González-García, María Ángeles Jiménez-Sousa, Ana Carrero, Víctor Hontañón, Jordi Navarro, Josep M. Guardiola, Amanda Fernández-Rodríguez, Salvador Resino, and the GESIDA Study Group
- Subjects
HIV/HCV coinfection ,Gene expression ,Immune system ,HCV clearance ,Interferon therapy ,PBMCs ,Medicine - Abstract
Abstract Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR
- Published
- 2021
- Full Text
- View/download PDF
10. Correction: Syndemic conditions and quality of life in the PISCIS Cohort of people living with HIV in Catalonia and the Balearic Islands: a cross sectional study
- Author
-
Jocelyn Mesías-Gazmuri, Cinta Folch, Jorge Palacio-Vieira, Andreu Bruguera, Laia Egea-Cortés, Carlos G. Forero, Juan Hernández, José M. Miró, Jordi Navarro, Melchor Riera, Joaquim Peraire, Lucía Alonso-García, Yesika Díaz, Jordi Casabona, and Juliana Reyes-Urueña
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 - Published
- 2023
- Full Text
- View/download PDF
11. Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response
- Author
-
Antonio Astorga-Gamaza, Judith Grau-Expósito, Joaquín Burgos, Jordi Navarro, Adrià Curran, Bibiana Planas, Paula Suanzes, Vicenç Falcó, Meritxell Genescà, and Maria J Buzon
- Subjects
HIV ,reservoir ,immune resistance ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Human immunodeficiency virus (HIV) establishes a persistent infection in heterogeneous cell reservoirs, which can be maintained by different mechanisms including cellular proliferation, and represent the main obstacle to curing the infection. The expression of the Fcγ receptor CD32 has been identified as a marker of the active cell reservoirs in people on antiretroviral therapy (ART), but if its expression has any role in conferring advantage for viral persistence is unknown. Here, we report that HIV-infected cells expressing CD32 have reduced susceptibility to natural killer (NK) antibody-dependent cell cytotoxicity (ADCC) by a mechanism compatible with the suboptimal binding of HIV-specific antibodies. Infected CD32 cells have increased proliferative capacity in the presence of immune complexes, and are more resistant to strategies directed to potentiate NK function. Remarkably, reactivation of the latent reservoir from antiretroviral-treated people living with HIV increases the pool of infected CD32 cells, which are largely resistant to the ADCC immune mechanism. Thus, we report the existence of reservoir cells that evade part of the NK immune response through the expression of CD32.
- Published
- 2022
- Full Text
- View/download PDF
12. A Prospective, Single-Blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Soft Tissue Open Surgery
- Author
-
Shankar Lakshman, Keith Aqua, Aleksandar Stefanovic, Srdjan Djurdjevic, Péter Nyirády, Péter Osváth, Ronald Davis, Arnold Bullock, Junliang Chen, Julia Ibañez, Gladis Barrera, Jordi Navarro-Puerto, and on behalf of the Fibrin Sealant Grifols in Soft Tissue Surgery Study Clinical Investigation Group
- Subjects
fibrin sealant grifols ,hemostasis ,plasma-derived ,soft tissue surgery ,surgicel ,Surgery ,RD1-811 - Abstract
Background/Purpose: Rapid hemostasis, an essential prerequisite of good surgical practice during surgical bleeding, including soft tissue open surgery, often requires adjunctive treatment. We evaluated the safety and hemostatic effectiveness of a human plasma-derived fibrin sealant (FS Grifols) in soft tissue open surgery. Methods: Patients with moderate soft tissue bleeding during open, urologic, gynecologic or general surgery were studied. The trial consisted of a preliminary phase (to familiarize investigators with the technique for FS Grifols application and the intraoperative procedures required by the clinical protocol) and a primary phase: in both phases, patients were randomized 1:1 to FS Grifols or Surgicel®. The primary efficacy endpoint, based on analysis of subjects in the primary phase of the study, was to evaluate whether FS Grifols was non-inferior to Surgicel® in achieving hemostasis, based on the proportion of subjects in both treatment groups who achieved hemostasis at the target bleeding site (TBS) by 4 min (T4) following the start of treatment application. Safety assessments included adverse events (AEs), vital signs, physical assessments, common clinical laboratory tests, viral markers, and immunogenicity. Results: A total of 224 subjects were randomized (primary phase): FS Grifols (N = 116), Surgicel® (N = 108). The 95% CI at T4 for the ratio of the proportion of patients achieving hemostasis in the two treatment groups was 1.064 (0.934, 1.213), indicating non-inferiority for FS Grifols vs. Surgicel®. The rate of hemostasis at the TBS by T4 in both phases of the study was higher in the FS Grifols treatment group (preliminary phase: 90.2%; primary phase: 82.8%) than in the Surgicel® treatment group (preliminary phase: 78.8%; primary phase: 77.8%). Overall, reported AEs were as expected in surgical patients and were similar between the two treatment groups. Conclusions: This study shows the non-inferiority in time to hemostasis of FS Grifols vs. Surgicel as an adjunct to hemostasis in patients undergoing soft tissue open surgery, and a similar rate of AEs.
- Published
- 2020
- Full Text
- View/download PDF
13. Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
- Author
-
Carla Serra-Peinado, Judith Grau-Expósito, Laura Luque-Ballesteros, Antonio Astorga-Gamaza, Jordi Navarro, Jenny Gallego-Rodriguez, Mario Martin, Adrià Curran, Joaquin Burgos, Esteban Ribera, Berta Raventós, Rein Willekens, Ariadna Torrella, Bibiana Planas, Rosa Badía, Felipe Garcia, Josep Castellví, Meritxell Genescà, Vicenç Falcó, and Maria J. Buzon
- Subjects
Science - Abstract
Here, the authors identify B lymphocyte antigen CD20 as a marker for HIV-infected T cells and provide evidence for the potential use of anti-CD20 antibodies in combination with latency reversing agents for depletion of viral reactivated CD4 T cells in patients on antiretroviral therapy.
- Published
- 2019
- Full Text
- View/download PDF
14. Particulated Autologous Chondral−Platelet-Rich Plasma Matrix Implantation (PACI) for Treatment of Full-Thickness Cartilage Osteochondral Defects
- Author
-
Ramón Cugat, M.D., Ph.D., Gonzalo Samitier, M.D., Ph.D., Gustavo Vinagre, M.D., Ph.D., Maria Sava, B.S., Eduard Alentorn-Geli, M.D., Ph.D., Montserrat García-Balletbó, M.D., Ph.D., Xavier Cuscó, M.D., Roberto Seijas, M.D., Ph.D., David Barastegui, M.D., Ph.D., Jordi Navarro, and Patricia Laiz
- Subjects
Orthopedic surgery ,RD701-811 - Abstract
Articular hyaline cartilage injuries can occur as a result of either traumatic of progressive degeneration. When the articular cartilage in a joint is damaged, it can cause joint pain and dysfunction, predisposing patients for the development of early-onset osteoarthritis. There are many restoration procedures available to treat these injuries, such as bone marrow−stimulation techniques, osteoarticular auto/allograft transplants, and autologous chondrocyte implantation. Each of these techniques has its own limitations, which led researchers to explore new regenerative and repair techniques to produce normal hyaline cartilage. The purpose of this Technical Note is to describe in detail the particulated autologous chondral−platelet-rich plasma matrix implantation (PACI) technique that could be used as a single-stage cartilage restoration procedure for treatment of full-thickness cartilage and osteochondral defects.
- Published
- 2021
- Full Text
- View/download PDF
15. Treatment of Partial Posterior Cruciate Ligament Injuries with Platelet-Rich Plasma in Growth Factors (PRGF) Intraligamentous Infiltration and a Specific Knee Brace
- Author
-
David Barastegui, Eduard Alentorn-Geli, Dhaval Gotecha, Marta Rius, Jordi Navarro, Xavier Cuscó, Roberto Seijas, and Ramón Cugat
- Subjects
pcl ,treatment ,prp ,growth factors ,knee brace ,Surgery ,RD1-811 - Abstract
Posterior cruciate ligament (PCL) injuries are not as common as other knee ligament injuries, but may present a challenging scenario for even skilled knee surgeons. Complete PCL tears are typically encountered in the setting of multiligament knee injuries and require surgical treatment. Isolated complete PCL injuries are uncommon and the best treatment is debated, and likely depends on the degree of symptoms and objective instability. However, many PCL injuries will be partial tears (grade I or II). The purpose of this chapter is to describe our treatment of choice for partial PCL injuries through a conservative approach. Level of evidence Level IV.
- Published
- 2021
- Full Text
- View/download PDF
16. Circumferential-Surrounding ('Sandwich') Meniscal Repair: A Salvage Technique to Save the Meniscus
- Author
-
Eduard Alentorn-Geli, M.D., M.Sc., Ph.D., F.E.B.O.T., F.A.C.G.M.E., Xavier Cuscó, M.D., Jordi Navarro, R.N., Roberto Seijas, M.D., Ph.D., David Barastegui, M.D., M.Sc., Ph.D., Gonzalo Samitier, M.D., Ph.D., F.E.B.O.T., Gilbert Steinbacher, M.D., Pedro Álvarez-Díaz, M.D., Ph.D., Jorge Ramírez, M.D., D.O., and Ramón Cugat, M.D., Ph.D.
- Subjects
Orthopedic surgery ,RD701-811 - Abstract
Meniscal injuries are extremely common in the general and athletic populations. The management strategy has switched from meniscectomy to meniscal-preserving techniques. It is nowadays extensively accepted that surgeons have to do their best to repair the meniscus and try to preserve as much tissue as possible. However, in many cases the tissue quality is poor and the tear pattern is complex. In such scenarios, meniscal repair has a lower success rate. In the present surgical technique, an arthroscopic all-inside circumferential-surrounding meniscal repair technique is presented. Any meniscal tissue or the meniscal rim is first debrided to a bleeding bed. Then, an all-inside device is used to create vertical sutures from capsule to capsule surrounding the entire meniscus (circumferential-surrounding). Care should be taken not to tighten the suture too much to avoid cutting the meniscal tissue. This easy and effective repair technique “packs” the meniscal tear fragments altogether and allows the surgeon to save the meniscus when facing with irreparable, degenerative, complex meniscus tears.
- Published
- 2020
- Full Text
- View/download PDF
17. A novel autologous-made matrix using hyaline cartilage chips and platelet-rich growth factors for the treatment of full-thickness cartilage or osteochondral defects: Preliminary results
- Author
-
Ramón Cugat, Eduard Alentorn-Geli, Jordi Navarro, Xavier Cuscó, Gilbert Steinbacher, Roberto Seijas, Pedro Álvarez-Díaz, David Barastegui, Patricia Laiz, Gonzalo Samitier, and Montserrat García-Balletbó
- Subjects
Orthopedic surgery ,RD701-811 - Abstract
Purpose: To report the clinical, functional, and magnetic resonance imaging (MRI)-based outcomes of a novel autologous-made matrix consisting of hyaline cartilage chips combined with mixed plasma poor rich in platelets clot and plasma rich in growth factors (PRGF) for the treatment of knee full-thickness cartilage or osteochondral defects. Methods: Between July 2015 and January 2018, all patients with full-thickness cartilage or osteochondral defects undergoing this novel cartilage restoration surgical technique were approached for eligibility. Indications for this procedure included traumatic or atraumatic full-thickness knee cartilage defects or osteochondritis dissecans. Patients were included if they had no concomitant use of stem cells, previous ipsilateral cartilage repair procedure, or follow-up was less than 10 months. The outcomes included data on current symptoms, physical exam, patient-reported, and functional outcomes (visual analogue scale (VAS) for pain, Lysholm score, Tegner activity scale, International Knee Documentation Committee (IKDC) subjective form, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, Lequesne index, and short form-12 (SF-12)) and the magnetic resonance observation of cartilage repair tissue (MOCART) score. These outcomes were compared to preoperative values, except for the MOCART score. Results: Fifteen patients were included in this preliminary study: mean (standard deviation (SD), range) follow-up 15.9 months (7.2, 10–32), age 26.8 years (12.1, 16–58), and body mass index 23.2 (2.1, 19.3–26.9). There were 14 men (93%) and 1 woman (7%). There was a statistically significant improvement between pre- and postoperative periods for VAS for pain ( p = 0.003), Lysholm score ( p = 0.002), IKDC subjective form ( p = 0.003), WOMAC for pain ( p = 0.005), WOMAC for stiffness ( p = 0.01), WOMAC for function ( p = 0.002), Lequesne Index ( p = 0.002), and SF-12 physical component summary ( p = 0.007). The postoperative mean (SD; range) MOCART score was 70 (12.4; 40–85). Conclusions: The use of this novel cartilage restoration surgical technique provides excellent clinical, functional, and MRI-based outcomes in young, active individuals with full-thickness cartilage or osteochondral defects. Level of evidence: Level IV—Therapeutic case series.
- Published
- 2019
- Full Text
- View/download PDF
18. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
- Author
-
Judith Grau-Expósito, Laura Luque-Ballesteros, Jordi Navarro, Adrian Curran, Joaquin Burgos, Esteban Ribera, Ariadna Torrella, Bibiana Planas, Rosa Badía, Mario Martin-Castillo, Jesús Fernández-Sojo, Meritxell Genescà, Vicenç Falcó, and Maria J Buzon
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Biology (General) ,QH301-705.5 - Abstract
Latency reversal agents (LRAs) have proven to induce HIV-1 transcription in vivo but are ineffective at decreasing the size of the latent reservoir in antiretroviral treated patients. The capacity of the LRAs to perturb the viral reservoir present in distinct subpopulations of cells is currently unknown. Here, using a new RNA FISH/flow ex vivo viral reactivation assay, we performed a comprehensive assessment of the viral reactivation capacity of different families of LRAs, and their combinations, in different CD4+ T cell subsets. We observed that a median of 16.28% of the whole HIV-reservoir induced HIV-1 transcripts after viral reactivation, but only 10.10% of these HIV-1 RNA+ cells produced the viral protein p24. Moreover, none of the LRAs were powerful enough to reactivate HIV-1 transcription in all CD4+ T cell subpopulations. For instance, the combination of Romidepsin and Ingenol was identified as the best combination of drugs at increasing the proportion of HIV-1 RNA+ cells, in most, but not all, CD4+ T cell subsets. Importantly, memory stem cells were identified as highly resistant to HIV-1 reactivation, and only the combination of Panobinostat and Bryostatin-1 significantly increased the number of cells transcribing HIV within this subset. Overall, our results validate the use of the RNA FISH/flow technique to assess the potency of LRAs among different CD4+ T cell subsets, manifest the intrinsic differences between cells that encompass the latent HIV reservoir, and highlight the difficulty to significantly impact the latent infection with the currently available drugs. Thus, our results have important implications for the rational design of therapies aimed at reversing HIV latency from diverse cellular reservoirs.
- Published
- 2019
- Full Text
- View/download PDF
19. Effects of autologous adipose-derived regenerative stem cells administered at the time of anterior cruciate ligament reconstruction on knee function and graft healing
- Author
-
Eduard Alentorn-Geli, Roberto Seijas, Adrián Martínez-De la Torre, Xavier Cuscó, Gilbert Steinbacher, Pedro Álvarez-Díaz, David Barastegui, Jordi Navarro, José Maria Serra-Renom, Betina Nishishinya, Jordi Català, Patricia Laiz, Montserrat García-Balletbó, and Ramón Cugat
- Subjects
Orthopedic surgery ,RD701-811 - Abstract
Purpose: To compare the healing and clinical outcomes of anterior cruciate ligament (ACL) reconstruction between patients with or without intraoperative administration of adipose-derived regenerative stem cells (ADRC). Methods: Between 2013 and 2014, the outcomes of 20 soccer players undergoing ACL reconstruction using bone–patellar tendon–bone autograft infiltrated with ADRC at the end of the procedure were compared to a historical, matched cohort of 19 soccer players undergoing the same procedure without ADRC. Outcomes were obtained at baseline, and 6 and 12 months postop for IKDC (International Knee Documentation Committee), Lysholm, and Lequesne, and at 2, 4, 6, and 12 months postop for VAS (visual analogue scale) for pain and graft maturation to evaluate the ligamentization process (magnetic resonance imaging (MRI)-based). Results: Both groups significantly improved the IKDC ( p < 0.001 in both groups), Lysholm ( p < 0.001 in both groups), Lequesne index ( p < 0.001 in both groups), VAS for pain ( p = 0.002 for the ADRC and p < 0.001 for the control group), and MRI scores ( p < 0.001 in both groups) in the 12 months postop compared to baseline scores. However, there were no significant differences in the improvement of the outcomes between groups across time ( p > 0.05). All patients returned to sports after surgery, but 8 (40%) patients in the ADRC and 13 (68.4%) patients in the control group had lower Tegner activity score at 12 months postop. Conclusions: Patients receiving ADRC at the time of ACL reconstruction significantly improved knee function and healing/maturation of the graft at 12 months. However, this improvement was not statistically significant compared to a control group undergoing ACL reconstruction alone.
- Published
- 2019
- Full Text
- View/download PDF
20. Gut Microbiota Linked to Sexual Preference and HIV Infection
- Author
-
Marc Noguera-Julian, Muntsa Rocafort, Yolanda Guillén, Javier Rivera, Maria Casadellà, Piotr Nowak, Falk Hildebrand, Georg Zeller, Mariona Parera, Rocío Bellido, Cristina Rodríguez, Jorge Carrillo, Beatriz Mothe, Josep Coll, Isabel Bravo, Carla Estany, Cristina Herrero, Jorge Saz, Guillem Sirera, Ariadna Torrela, Jordi Navarro, Manel Crespo, Christian Brander, Eugènia Negredo, Julià Blanco, Francisco Guarner, Maria Luz Calle, Peer Bork, Anders Sönnerborg, Bonaventura Clotet, and Roger Paredes
- Subjects
HIV-1 ,Microbiome ,Microbiota ,16S rDNA ,Prevotella ,Bacteroides ,Medicine ,Medicine (General) ,R5-920 - Abstract
The precise effects of HIV-1 on the gut microbiome are unclear. Initial cross-sectional studies provided contradictory associations between microbial richness and HIV serostatus and suggested shifts from Bacteroides to Prevotella predominance following HIV-1 infection, which have not been found in animal models or in studies matched for HIV-1 transmission groups. In two independent cohorts of HIV-1-infected subjects and HIV-1-negative controls in Barcelona (n = 156) and Stockholm (n = 84), men who have sex with men (MSM) predominantly belonged to the Prevotella-rich enterotype whereas most non-MSM subjects were enriched in Bacteroides, independently of HIV-1 status, and with only a limited contribution of diet effects. Moreover, MSM had a significantly richer and more diverse fecal microbiota than non-MSM individuals. After stratifying for sexual orientation, there was no solid evidence of an HIV-specific dysbiosis. However, HIV-1 infection remained consistently associated with reduced bacterial richness, the lowest bacterial richness being observed in subjects with a virological-immune discordant response to antiretroviral therapy. Our findings indicate that HIV gut microbiome studies must control for HIV risk factors and suggest interventions on gut bacterial richness as possible novel avenues to improve HIV-1-associated immune dysfunction.
- Published
- 2016
- Full Text
- View/download PDF
21. Articulated Bone Block for Posterior Cruciate Ligament Reconstruction Using Bone–Patellar Tendon–Bone Autograft: Surgical Technique to Facilitate Graft Passage
- Author
-
Ramón Cugat, M.D., Ph.D., Eduard Alentorn-Geli, M.D., M.Sc., Ph.D., F.E.B.O.T., Xavier Cuscó, M.D., Jordi Navarro, R.N., Gilbert Steinbacher, M.D., Pedro Álvarez-Díaz, M.D., Ph.D., Roberto Seijas, M.D., Ph.D., David Barastegui, M.D., M.Sc., Ph.D., and Montse García-Balletbó, M.D., Ph.D.
- Subjects
Orthopedic surgery ,RD701-811 - Abstract
Posterior cruciate ligament reconstruction using the transtibial technique provides successful clinical outcomes. However, a bone–patellar tendon–bone (BTB) autograft with the transtibial technique has not been used by some surgeons because of concerns with graft passage from the tibial to the femoral tunnels (sharp turn) that can damage graft fibers. In the present surgical technique, an arthroscopic, transtibial, single-bundle technique for posterior cruciate ligament reconstruction using the BTB autograft with an easy and effective technical tip to facilitate graft passage is presented. Once the BTB is harvested, the femoral bone block is divided into 2 equal-sized blocks providing an articulated structure while preserving the tendon component. This facilitates the passage of the BTB tendon once it is entered in the posterior tibia and the graft has to make a sharp turn to reach the femoral tunnel. This easy and effective technique tip may avoid graft damage during the sharp turn, while maintaining all the advantages of a BTB autograft (bone-to-bone healing, own tissue with fast incorporation, and strong fixation and stability).
- Published
- 2018
- Full Text
- View/download PDF
22. A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients
- Author
-
Judith Grau-Expósito, Carla Serra-Peinado, Lucia Miguel, Jordi Navarro, Adrià Curran, Joaquin Burgos, Imma Ocaña, Esteban Ribera, Ariadna Torrella, Bibiana Planas, Rosa Badía, Josep Castellví, Vicenç Falcó, Manuel Crespo, and Maria J. Buzon
- Subjects
viral persistence ,viral reactivation ,viral reservoirs ,human immunodeficiency virus ,Microbiology ,QR1-502 - Abstract
ABSTRACT Cells that actively transcribe HIV-1 have been defined as the “active viral reservoir” in HIV-infected individuals. However, important technical limitations have precluded the characterization of this specific viral reservoir during both treated and untreated HIV-1 infections. Here, we used a novel single-cell RNA fluorescence in situ hybridization-flow cytometry (FISH-flow) assay that requires only 15 million unfractionated peripheral blood mononuclear cells (PBMCs) to characterize the specific cell subpopulations that transcribe HIV RNA in different subsets of CD4+ T cells. In samples from treated and untreated HIV-infected patients, effector memory CD4+ T cells were the main cell population supporting HIV RNA transcription. The number of cells expressing HIV correlated with the plasma viral load, intracellular HIV RNA, and proviral DNA quantified by conventional methods and inversely correlated with the CD4+ T cell count and the CD4/CD8 ratio. We also found that after ex vivo infection of unstimulated PBMCs, HIV-infected T cells upregulated the expression of CD32. In addition, this new methodology detected increased numbers of primary cells expressing viral transcripts and proteins after ex vivo viral reactivation with latency reversal agents. This RNA FISH-flow technique allows the identification of the specific cell subpopulations that support viral transcription in HIV-1-infected individuals and has the potential to provide important information on the mechanisms of viral pathogenesis, HIV persistence, and viral reactivation. IMPORTANCE Persons infected with HIV-1 contain several cellular viral reservoirs that preclude the complete eradication of the viral infection. Using a novel methodology, we identified effector memory CD4+ T cells, immune cells preferentially located in inflamed tissues with potent activity against pathogens, as the main cells encompassing the transcriptionally active HIV-1 reservoir in patients on antiretroviral therapy. Importantly, the identification of such cells provides us with an important target for new therapies designed to target the hidden virus and thus to eliminate the virus from the human body. In addition, because of its ability to identify cells forming part of the viral reservoir, the assay used in this study represents an important new tool in the field of HIV pathogenesis and viral persistence.
- Published
- 2017
- Full Text
- View/download PDF
23. Treatment of Knee Osteochondral Lesions Using a Novel Clot of Autologous Plasma Rich in Growth Factors Mixed with Healthy Hyaline Cartilage Chips and Intra-Articular Injection of PRGF
- Author
-
Ramón Cugat, Eduard Alentorn-Geli, Gilbert Steinbacher, Pedro Álvarez-Díaz, Xavier Cuscó, Roberto Seijas, David Barastegui, Jordi Navarro, Patricia Laiz, and Montserrat García-Balletbó
- Subjects
Orthopedic surgery ,RD701-811 - Abstract
Knee cartilage or osteochondral lesions are common and challenging injuries. To date, most symptomatic lesions warrant surgical treatment. We present two cases of patients with knee osteochondral defects treated with a one-step surgical procedure consisting of an autologous-based matrix composed of healthy hyaline cartilage chips, mixed plasma poor-rich in platelets clot, and plasma rich in growth factors (PRGF). Both patients returned to playing soccer at the preinjury activity level and demonstrated excellent defect filling in both magnetic resonance imaging and second-look arthroscopy (in one of them). The use of a clot of autologous plasma poor in platelets with healthy hyaline cartilage chips and intra-articular injection of plasma rich in platelets is an effective, easy, and cheap option to treat knee cartilage injuries in young and athletic patients.
- Published
- 2017
- Full Text
- View/download PDF
24. Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue.
- Author
-
Sara Morón-López, Maria C Puertas, Cristina Gálvez, Jordi Navarro, Anna Carrasco, Maria Esteve, Josep Manyé, Manel Crespo, Maria Salgado, and Javier Martinez-Picado
- Subjects
Medicine ,Science - Abstract
BACKGROUND:The implementation of successful strategies to achieve an HIV cure has become a priority in HIV research. However, the current location and size of HIV reservoirs is still unknown since there are limited tools to evaluate HIV latency in viral sanctuaries such as gut-associated lymphoid tissue (GALT). As reported in the so called "Boston Patients", despite undetectable levels of proviral HIV-1 DNA in blood and GALT, viral rebound happens in just few months after ART interruption. This fact might imply that current methods are not sensitive enough to detect residual reservoirs. Showing that, it is imperative to improve the detection and quantification of HIV-1 reservoir in tissue samples. Herein, we propose a novel non-enzymatic protocol for purification of Lamina Propria Leukocytes (LPL) from gut biopsies combined to viral HIV DNA (vDNA) quantification by droplet digital PCR (ddPCR) to improve the sensitivity and accuracy of viral reservoir measurements (LPL-vDNA assay). METHODS:Endoscopic ileum biopsies were sampled from 12 HIV-1-infected cART-suppressed subjects. We performed a DTT/EDTA-based treatment for epithelial layer removal followed by non-enzymatic disruption of the tissue to obtain lamina propria cell suspension (LP). CD45+ cells were subsequently purified by flow sorting and vDNA was determined by ddPCR. RESULTS:vDNA quantification levels were significantly higher in purified LPLs (CD45+) than in bulk LPs (p
- Published
- 2017
- Full Text
- View/download PDF
25. Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns.
- Author
-
César Garriga, Sandra Manzanares-Laya, Patricia García de Olalla, Pilar Gorrindo, Sabela Lens, Ricard Solà, María Martínez-Rebollar, Montserrat Laguno, Jordi Navarro, Xavier Torras, Mercè Gurguí, María-Jesús Barberá, Josep Quer, Eva Masdeu, Pere Simón, Miriam Ros, Anna de Andrés, and Joan A Caylà
- Subjects
Medicine ,Science - Abstract
The aims of this study were to describe the evolution of acute hepatitis C virus (HCV) infections since 2004 and to determine its associated factors. Acute HCV infections diagnosed in Barcelona from 2004 to 2015 were included. Incidence ratios (IR) were then estimated for sex and age groups. Cases were grouped between 2004-2005, 2006-2011 and 2012-2015, and their incidence rate ratios (IRR) were calculated. In addition, risk factors for acute HCV infection were identified using multinomial logistic regression for complete, available and multiple imputed data. 204 new HCV cases were identified. Two peaks of higher IR of acute HCV infection in 2005 and 2013 were observed. Men and those aged 35-54 had higher IR. IRR for men was 2.9 times greater than in women (95% confidence intervals (CI): 1.8 ‒ 4.7). Factors related to the period 2012-2015 (versus 2006-2011) were: a) sexual risk factor for transmission versus nosocomial (relative-risk ratio (RRR): 13.0; 95% CI: 2.3 ‒ 72.1), b) higher educated versus lower (RRR: 5.4; 95% CI: 1.6 ‒ 18.7), and c) HIV co-infected versus not HIV-infected (RRR: 53.1; 95% CI: 5.7 ‒ 492.6). This is one of the few studies showing IR and RRRs of acute HCV infections and the first focused on a large city in Spain. Sexual risk for transmission between men, higher educational level and HIV co-infection are important factors for understanding current HCV epidemic. There has been a partial shift in the pattern of the risk factor for transmission from nosocomial to sexual.
- Published
- 2017
- Full Text
- View/download PDF
26. Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain
- Author
-
Jordi Navarro, Adrian Curran, Berta Raventós, Jorge García, Paula Suanzes, Vicente Descalzo, Patricia Álvarez, Nuria Espinosa, Marisa Luisa Montes, Inés Suárez-García, Concha Amador, Roberto Muga, Vicenç Falcó, and Joaquín Burgos
- Subjects
Internal Medicine - Published
- 2023
27. Customary light-gauge steel framing construction with flat strap bracing. Seismicity limits for short to mid-rise buildings in Europe
- Author
-
GRANADOS, JORDI NAVARRO, primary, Casafont, Miquel, additional, Bové, Oriol, additional, Bonada, Jordi, additional, and López-Almansa, Francisco, additional
- Published
- 2023
- Full Text
- View/download PDF
28. Customary light-gauge steel framing construction with flat strap bracing. Seismicity limits for short to mid-rise buildings in Europe
- Author
-
JORDI NAVARRO GRANADOS, Miquel Casafont, Oriol Bové, Jordi Bonada, and Francisco López-Almansa
- Abstract
Ordinary (customary) light gauge steel framing is a convenient construction technology; however, given the studs low axial capacity, has been mainly considered for short buildings in low seismicity regions. This paper investigates the bounds of this type of steel framing (in moderate and high seismicity areas) by designing the structures of three representative 5, 7 and 10-story buildings in order to examine their feasibility. The necessity of using built-up columns consisting of two or more sections is observed. The axial capacity of studs is estimated by code-type analyses. The critical buckling stress is determined with well-known closed-form expressions; as they do not contemplate the flexibility of the screwed connections (in built-up sections), the obtained results are complemented with those of Finite Strip Method and Generalized Beam Theory formulations.
- Published
- 2023
29. Energy Control: Observatorio de consumos, riesgos y cuidados. Informe Técnico 2022
- Author
-
Vidal-Giné, Claudio, López, Jordi Navarro, and Piedra, Diego Fernández
- Published
- 2023
- Full Text
- View/download PDF
30. mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis E Screening in patients with immune impairment and increased transaminases levels)
- Author
-
Mar Riveiro-Barciela, Luisa Roade, Joan Martínez-Camprecios, Judit Vidal-González, Basilio Rodríguez-Diez, Manel Perelló, Guillermo Ortí, Virginia Robles-Alonso, Cristina Berastegui, Jordi Navarro, Fernando Martínez-Valle, Itxarone Bilbao, Lluis Castells, Meritxell Ventura-Cots, Jordi Llaneras, Ariadna Rando-Segura, Xavier Forns, Sabela Lens, Martín Prieto, María García-Eliz, Arkaitz Imaz, Francisco Rodríguez-Frías, Maria Buti, and Rafael Esteban
- Subjects
Hepatology ,Gastroenterology - Published
- 2023
31. Pharmacokinetics, efficacy and safety of a novel fibrinogen concentrate in pediatric patients with congenital afibrinogenemia
- Author
-
Claudia Djambas Khayat, Jordi Navarro-Puerto, Cecil Reuben Ross, Kannan Subramanian, Nijalingappa K. Kalappanavar, Karen Rucker, Wei Liang, and Elsa Mondou
- Subjects
Hematology ,General Medicine - Abstract
Congenital afibrinogenemia treatment with plasma-derived fibrinogen concentrates in pediatric patients is limited. This study investigated the pharmacokinetics, surrogate efficacy, and safety of a plasma-derived fibrinogen concentrate (FIB Grifols) in pediatric patients with congenital afibrinogenemia.Patients aged18 years old diagnosed with congenital afibrinogenemia were included in this prospective, multinational, phase 1-2, single-arm study. After a single dose of a plasma-derived fibrinogen concentrate (70 mg/kg body weight), pharmacokinetic parameters were determined from plasma fibrinogen activity (Clauss method) and antigen method (ELISA), and calculated by noncompartmental and population pharmacokinetic (popPK) models. Patients were followed up over 14 days. Efficacy variables were the mean change on thromboelastographic variables (maximum clot firmness [MCF], alpha angle [α]) and coagulation tests (prothrombin time, activated partial thromboplastin time, and thrombin time) 1 h postinfusion. Safety parameters were assessed.Eleven patients with a median (range) age 8.80 (3.7-12.7) years were treated with the plasma-derived fibrinogen concentrate. Using the popPK modeling, fibrinogen activity reached a mean (standard deviation) Cmax of 1.3 (0.225) g/l, half-life (t1/2) of 60.6 (4.48) h and incremental in vivo recovery (IVR) of 1.86 (0.322) (mg/dl)/(mg/kg). Surrogate efficacy was demonstrated by significant increase in MCF (9.23 [3.94] mm; P 0.001; 95% confidence interval 6.58, 11.87). All coagulation times were significantly shortened after fibrinogen concentrate infusion. Adverse events were mild or moderate in severity, and unrelated to fibrinogen concentrate.In pediatric patients with congenital afibrinogenemia, plasma-derived fibrinogen concentrate revealed a favorable and specific pharmacokinetic profile, demonstrated efficacy in coagulation and was safe and well tolerated.
- Published
- 2022
32. Exploratory study of an oral screening dysplasia program for HIV-infected men who have sex with men
- Author
-
Angela Callejo, Maria del Mar Molina, Maria Carme Dinares, Javier Hernández-Losa, Bibiana Planas, Jorge Garcia, Adria Curran, Jordi Navarro, Paula Suanzes, Vicenç Falcó, Joaquin Burgos, Institut Català de la Salut, [Callejo A] Universitat Autònoma de Barcelona, Bellaterra, Spain. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, Department of Otorhinolaryngology. [Del Mar Molina M, Planas B, Garcia J, Curran A, Navarro J, Suanzes P, Falcó V, Burgos J] Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Dinares MC, Hernández-Losa J] Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Adult ,Male ,Anus - Malalties - Epidemiologia ,Papillomavirus Infections ,Immunology ,Anal Canal ,HIV Infections ,Virus Diseases::Virus Diseases::Sexually Transmitted Diseases::Sexually Transmitted Diseases, Viral::HIV Infections [DISEASES] ,Anus Neoplasms ,Infeccions per VIH - Epidemiologia ,Virus Diseases::Virus Diseases::Tumor Virus Infections::Papillomavirus Infections [DISEASES] ,Sexual and Gender Minorities ,Infectious Diseases ,Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Rectal Neoplasms::Anus Neoplasms [DISEASES] ,Prevalence ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales::neoplasias del recto::neoplasias del ano [ENFERMEDADES] ,Humans ,Immunology and Allergy ,virosis::virosis::enfermedades de transmisión sexual::enfermedades virales de transmisión sexual::infecciones por VIH [ENFERMEDADES] ,Prospective Studies ,Homosexuality, Male ,virosis::virosis::infecciones por virus oncógenos::infecciones por Papillomavirus [ENFERMEDADES] ,Papil·lomavirus ,Papillomaviridae - Abstract
Dysplasia; Screening; HIV-infected Displasia; Cribado; Infectado por el VIH Displàsia; Cribratge; Infectat pel VIH Background: HIV-infected men who have sex with men (MSM) are at high risk to develop human papilloma virus (HPV)-related oropharyngeal cancer. The aim of our study was to assess the usefulness of a pilot oral dysplasia screening program and its correlation with an anal dysplasia screening program. Methods: This was a prospective study with HIV-infected MSM. Oral and anal screenings were performed based on HPV determination, liquid cytology, direct and microscopy oral examinations, high-resolution anoscopy and biopsies, if necessary. Results: A total of 103 patients were included. The mean age of the patients was 44.6 years, 55.3% were smokers, and 57.3% had a history of previous anal high-grade squamous intraepithelial lesions (HSILs). The prevalence of oral HPV infections was 14% (9% HPV-high risk), the prevalence of abnormal cytology was 25.2%, and in 4.8% of the patients, oral examinations showed suspicious HSILs. Oral microscopy did not detect additional lesions that visual inspection. Five oral biopsies were performed and the results were normal. No risk factors for oral HPV infections were identified. The prevalence of anal HPV infections was 88.3% (76.7% HPV-high risk), 52.9% of the patients had altered cytology, and in 45.6% anoscopy showed changes suggestive of HSILs. Seventy-two anal biopsies were performed, detecting 25 cases of HSILs (24.3%). A poor correlation was observed between oral and anal HPV infections (κ = 0.037). Conclusions: The prevalence of oral HPV infections, abnormal cytology and lesions in HIV-infected MSM was low, and their correlation with anal HPV-related lesions was slight. These results confirm the current barriers to oral dysplasia screening techniques. Study funded by program MISP of MSD (Merck HPV Investigator Study Program). MISP project code 58237.
- Published
- 2022
33. HIV and liver disease
- Author
-
Jordi, Navarro
- Subjects
Acquired Immunodeficiency Syndrome ,Infectious Diseases ,Anti-Retroviral Agents ,Non-alcoholic Fatty Liver Disease ,Antiretroviral Therapy, Highly Active ,Humans ,HIV Infections ,Pharmacology (medical) ,General Medicine - Abstract
Liver-related diseases are associated with the high levels of morbidity and mortality in people living with HIV. Between 13% and 18% of all-cause mortality in HIV-infected patients involves a liver-related damage, this being one of the main causes of death not related to acquired immunodeficiency syndrome (AIDS). People living with HIV, even when the disease is under control, are more likely to develop pathologies and complications of a liver-related origin than the general population, both due to common causes such as alcoholism, non-alcoholic fatty liver disease, hepatic viral infections and ageing, in addition to specific HIV-related processes such as antiretroviral treatment toxicity and liver damage inherent to HIV infection. On the other hand, some antiretroviral drugs may have a beneficial effect in reversing liver fibrosis in patients with HIV and chronic liver disease. This paper reviews the main risk factors associated with liver disease in people living with HIV and the role of antiretroviral therapy (ART) in this disease.
- Published
- 2022
34. Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
- Author
-
Ana Malvar, Valeria Alberton, Bruno Lococo, Maria Lourenco, Joaquin Martinez, Lucrecia Burna, Celeste Besso, Jordi Navarro, Haikady N Nagaraja, Aastha Khatiwada, Bethany Wolf, and Brad Rovin
- Subjects
Rheumatology ,General Medicine - Abstract
ObjectiveThis study investigated changes in kidney histology over time in patients with lupus nephritis (LN) undergoing immunosuppressive treatment.MethodsPatients with proliferative±membranous LN were studied. After a diagnostic kidney biopsy (Bx1), patients had protocol biopsy 2 (Bx2) at 9 (6–15) months and protocol biopsy 3 (Bx3) at 42 (28–67) months. Kidney histological activity and chronicity indices (AI, CI) were measured.ResultsAI declined in a biphasic fashion, falling rapidly between Bx1 and Bx2 and then more slowly between Bx2 and Bx3. Patients were divided into those who achieved histological remission, defined as an AI=0 at Bx3 (group 1), and those with persistent histological activity (AI >0) at Bx3 (group 2). The early decline in AI was 1.6 times greater (95% CI 1.30, 1.91) in group 1 than group 2 (p=0.01). Between Bx2 and Bx3, the AI decline was 2.19-fold greater (95% CI 2.09, 2.29) in group 1 versus group 2 (p=7.34×10−5). Individual histological components of the AI resolved at different rates. Inflammatory lesions like glomerular crescents, karyorrhexis and necrosis mostly resolved by Bx2, whereas endocapillary hypercellularity, subendothelial hyaline deposits and interstitial inflammation resolved slowly, accounting for residual histological activity at biopsy 3 in group 2. In contrast, CI increased rapidly, by 0.15 units/month between Bx1 and Bx2, then plateaued. There were no differences in the rate of accumulation of chronic damage between group 1 and group 2. The increase in CI was significantly related to the severity of glomerular crescents (p=0.044), subendothelial hyaline deposits (p=0.002) and interstitial inflammation (p=0.015) at Bx1.ConclusionsLN histological activity takes months to years to resolve, providing a rationale for the need of long-term, well-tolerated maintenance immunosuppression. Despite responding, LN kidneys accrue chronic damage early during treatment. This finding provides an explanation for the association of chronic progressive kidney disease with recurrent episodes of LN.
- Published
- 2023
35. Treatment of Partial Posterior Cruciate Ligament Injuries with Platelet-Rich Plasma in Growth Factors (PRGF) Intraligamentous Infiltration and a Specific Knee Brace
- Author
-
Dhaval Gotecha, Marta Rius, Eduard Alentorn-Geli, David Barastegui, Xavier Cuscó, Jordi Navarro, Ramón Cugat, and Roberto Seijas
- Subjects
medicine.medical_specialty ,PRP ,lcsh:Surgery ,macromolecular substances ,growth factors ,medicine ,Surgical treatment ,treatment ,business.industry ,Intraligamentous ,technology, industry, and agriculture ,knee brace ,lcsh:RD1-811 ,equipment and supplies ,musculoskeletal system ,Brace ,Surgery ,Knee ligament ,medicine.anatomical_structure ,PCL ,Platelet-rich plasma ,Posterior cruciate ligament ,Perspective ,Tears ,business ,Knee injuries - Abstract
Posterior cruciate ligament (PCL) injuries are not as common as other knee ligament injuries, but may present a challenging scenario for even skilled knee surgeons. Complete PCL tears are typically encountered in the setting of multiligament knee injuries and require surgical treatment. Isolated complete PCL injuries are uncommon and the best treatment is debated, and likely depends on the degree of symptoms and objective instability. However, many PCL injuries will be partial tears (grade I or II). The purpose of this chapter is to describe our treatment of choice for partial PCL injuries through a conservative approach. Level of evidence Level IV.
- Published
- 2021
36. Author response: Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response
- Author
-
Antonio Astorga-Gamaza, Judith Grau-Expósito, Joaquín Burgos, Jordi Navarro, Adrià Curran, Bibiana Planas, Paula Suanzes, Vicenç Falcó, Meritxell Genescà, and Maria J Buzon
- Published
- 2022
37. Incidence of malignancy in a Spanish cohort of patients infected by the human immunodeficiency virus
- Author
-
Joaquin Burgos, Jordi Navarro, Berta Raventós, Adria Curran, Mario Martin-Castillo, Jorge García, Esperanza Cañas-Ruano, Vicenç Falcó, Esteban Ribera, and Paula Suanzes
- Subjects
Male ,medicine.medical_specialty ,Population ,HIV Infections ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Lung cancer ,education ,Sarcoma, Kaposi ,Retrospective Studies ,education.field_of_study ,business.industry ,Incidence ,Incidence (epidemiology) ,Mortality rate ,HIV ,Cancer ,Retrospective cohort study ,medicine.disease ,Cancer registry ,Spain ,Cohort ,Female ,business - Abstract
A higher incidence of malignancies has been described in patients with HIV infection compared to the general population.Observational retrospective study in patients with HIV infection followed up at the Vall d'Hebron University Hospital (Barcelona, Spain) between 2009 and 2017. The objective of this research was to estimate the incidence of malignancies in HIV patients and their surveillance. Age and sex-adjusted incidence was compared to the incidence calculated by the Spanish Cancer Registry network (REDECAN) in 2015.We included 2,773 patients (41,238 patients-year). Two hundred and eleven malignancies were diagnosed in 182 patients. Non-AIDS defining cancers accounted for 78.2% of the malignancies. The global incidence of cancer was 485 cases per 100,000 person-years. Twenty-year mortality rate was 31.2% in patients with cancer and 7.8% in patients without cancer. In men, adjusted for age, the incidence of malignancies was higher than the incidence in the general population (978.4 vs. 641 cases per 100,000 person-years, P.001). The most common malignancies in men were lung cancer, Kaposi sarcoma and Hodgkin lymphoma. In women, the incidence of malignancies was not higher than in the general population (340.6 vs. 404.7 cases per 100,000 person-years, P=.27). The most common malignancies among women were lung cancer, head and neck cancer, cervical cancer and Hodgkin's lymphoma.Men with HIV infection showed a statistically significant higher incidence of malignancies compared to the general Spanish population. Lung cancer was the most common non-AIDS defining cancer.
- Published
- 2020
38. Incidencia de neoplasias en una cohorte española de pacientes con infección por el virus de la inmunodeficiencia humana
- Author
-
Berta Raventós, Jordi Navarro, Joaquin Burgos, Mario Martin-Castillo, Esteban Ribera, Esperanza Cañas-Ruano, Vicenç Falcó, Adria Curran, Paula Suanzes, and Jorge García
- Subjects
Gynecology ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,Medicine ,030212 general & internal medicine ,General Medicine ,business - Abstract
Resumen Introduccion Se ha descrito una mayor incidencia de neoplasias en los pacientes con infeccion por VIH en comparacion con la poblacion general. Pacientes y metodos Estudio observacional retrospectivo de la poblacion infectada por VIH en seguimiento en el Hospital Vall d’Hebron (Barcelona) entre 2009 y 2017. El objetivo de este estudio fue estimar la incidencia de neoplasias en estos pacientes con infeccion por VIH y su supervivencia. Se comparo la incidencia ajustada por edad y sexo en dicha poblacion con la calculada por la Red Espanola de Registros de Cancer (REDECAN) en 2015. Resultados Se incluyeron 2.773 pacientes (41.238 pacientes-ano). Se diagnosticaron 211 canceres en 182 pacientes. El 78,2% de las neoplasias fueron no definitorias de sida (NNDS). La tasa global de incidencia de cancer fue 485 neoplasias por 100.000 pacientes-ano. La mortalidad a 20 anos en pacientes con cancer fue del 31,2%, y del 7,8% en pacientes sin cancer. En varones, ajustada por edad, la incidencia de neoplasias fue mayor que en la poblacion general (978,4 vs. 641 por 100.000 pacientes-ano, p Conclusiones Los varones con infeccion por VIH presentaron una incidencia significativamente mayor de cancer que la poblacion espanola del mismo sexo. Los carcinomas pulmonares fueron las NNDS mas frecuentes.
- Published
- 2020
39. Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients
- Author
-
Ana, Carrero, Juan, Berenguer, Víctor, Hontañón, Josep M, Guardiola, Jordi, Navarro, Miguel A, von Wichmann, María J, Téllez, Carmen, Quereda, Ignacio, Santos, José, Sanz, María J, Galindo, José, Hernández-Quero, María A, Jiménez-Sousa, Leire, Pérez-Latorre, José M, Bellón, Salvador, Resino, Herminia, Esteban, Esteban, Martínez, Juan, González-García, H, Esteban, Ministerio de Sanidad, Servicios Sociales e Igualdad (España), Instituto de Salud Carlos III, and Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
- Subjects
musculoskeletal diseases ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Sofosbuvir ,Hepatitis C virus ,Osteoporosis ,HIV Infections ,Hepacivirus ,medicine.disease_cause ,bone ,Antiviral Agents ,Gastroenterology ,Polyethylene Glycols ,Bone remodeling ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Bone Density ,Pegylated interferon ,Internal medicine ,Ribavirin ,Humans ,Medicine ,030212 general & internal medicine ,Femoral neck ,Coinfection ,business.industry ,biomarkers ,HIV ,Interferon-alpha ,virus diseases ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,osteoporosis ,digestive system diseases ,Recombinant Proteins ,Infectious Diseases ,medicine.anatomical_structure ,chemistry ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Background Little is known about the effects of eradication of hepatitis C virus (HCV) on bone mineral density (BMD) and biomarkers of bone remodeling in human immunodeficiency virus (HIV)/HCV-coinfected patients. Methods We prospectively assessed standardized BMD (sBMD) at the lumbar spine and femoral neck, World Health Organization BMD categories at both sites, and plasma concentrations of soluble receptor activator of NF-κβ ligand (sRANKL), and osteoprotegerin (OPG) at baseline (the date of initiation of anti-HCV therapy) and at 96 weeks. Results A total of 238 patients were included. The median age was 49.5 years, 76.5% were males, 48.3% had cirrhosis, 98.3% were on antiretroviral therapy, median CD4+ cell count was 527 cells/μL, and 86.6% had HIV-1 RNA Conclusions SVR was not associated with significant changes in BMD nor biomarkers of bone remodeling in HIV/HCV-coinfected persons.
- Published
- 2020
40. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping
- Author
-
A Antela, Coral García Vallecillos, Leopoldo Muñoz Moreno, Fernando Montolio, Hortensia Álvarez, M Casadellà, Irene Portilla, Bibiana Planas, Félix Gutiérrez, Daniel Podzamczer, Sergio Padilla, R Paredes, Arkaitz Imaz, María Pilar Carmona, Maria Casadellà, Alfredo Rodríguez, M Montero-Alonso, Xabier Kortajarena, Isabel Bravo, M Masiá, Adria Curran, J Navarro, Antonio Ocampo, P Carmona-Oyaga, Vicente Boix, Marc Noguera-Julian, M Noguera-Julian, J R Santos, L Pérez-Martínez, J Sanz, Josean A Iribarren, Jordi Navarro, M J Vivancos, Anna Chamorro, Maialen Ibarguren, Celia Miralles, Juan José Ramos González, José Hernández Quero, Esperanza Merino, Cristina Miranda, A Imaz, Pilar Barrufet, Jèssica Muñoz Rodríguez, N Valcarce-Pardeiro, Maria Gracia Mateo, Lluís Force, Ángela Gutiérrez Liarte, A Ocampo, L Muñoz-Medina, Joaquín Portilla, José Ramón Blanco, Livia Giner, P Domingo, P Barrufet, Ana Mariño, Laura Pérez-Martínez, J Pasquau, Diego Torrús, María del, José R. Santos, Araceli Adsuar, Santiago Moreno, Ana Gómez Berrocal, Ariadna Torrella, Jesús Sanz, Melissa Carreres, Nieves Valcarce Pardeiro, Juan Pasquau, Hernando Knobel, Mar Masiá, Marta Montero-Alonso, J Villar-García, Sergio Reus, Catalina Robledano, J Portilla, Rafael Micán, Judit Villar-García, Antonio Antela, R Micán-Rivera, Pere Domingo, María J Pérez-Elías, Roger Paredes, Fernando Dronda, María Jesús Vivancos, Mar Gutierrez, and Marcos Diez
- Subjects
Microbiology (medical) ,Genotype ,Population ,Integrase inhibitor ,HIV Infections ,HIV Integrase ,Drug resistance ,Virus ,Cohort Studies ,Drug Resistance, Viral ,Humans ,Medicine ,Pharmacology (medical) ,Protease inhibitor (pharmacology) ,HIV Integrase Inhibitors ,Prospective Studies ,education ,Genotyping ,Pharmacology ,education.field_of_study ,Integrases ,biology ,business.industry ,Virology ,Reverse transcriptase ,Integrase ,Infectious Diseases ,Spain ,Mutation ,HIV-1 ,biology.protein ,business - Abstract
BackgroundTransmission of resistance mutations to integrase strand transfer inhibitors (INSTIs) in HIV-infected patients may compromise the efficacy of first-line antiretroviral regimens currently recommended worldwide. Continued surveillance of transmitted drug resistance (TDR) is thus warranted.ObjectivesWe evaluated the rates and effects on virological outcomes of TDR in a 96 week prospective multicentre cohort study of ART-naive HIV-1-infected subjects initiating INSTI-based ART in Spain between April 2015 and December 2016.MethodsPre-ART plasma samples were genotyped for integrase, protease and reverse transcriptase resistance using Sanger population sequencing or MiSeq™ using a ≥ 20% mutant sensitivity cut-off. Those present at 1%–19% of the virus population were considered to be low-frequency variants.ResultsFrom a total of 214 available samples, 173 (80.8%), 210 (98.1%) and 214 (100.0%) were successfully amplified for integrase, reverse transcriptase and protease genes, respectively. Using a Sanger-like cut-off, the overall prevalence of any TDR, INSTI-, NRTI-, NNRTI- and protease inhibitor (PI)-associated mutations was 13.1%, 1.7%, 3.8%, 7.1% and 0.9%, respectively. Only three (1.7%) subjects had INSTI TDR (R263K, E138K and G163R), while minority variants with integrase TDR were detected in 9.6% of subjects. There were no virological failures during 96 weeks of follow-up in subjects harbouring TDR as majority variants.ConclusionsTransmitted INSTI resistance remains rare in Spain and, to date, is not associated with virological failure to first-line INSTI-based regimens.
- Published
- 2020
41. Exploration of clients living with HIV needs for reporting on experiences with sex
- Author
-
Jordi Navarro Mercadé, Maria Feijoo-Cid, Juan M. Leyva-Moral, Bibiana Planas Ribas, Rosa Badia Royes, Mario Martín Castillo, Ariadna Torrella Domingo, and Mariela Aguayo-González
- Subjects
Adult ,Male ,medicine.medical_specialty ,Patients ,Sexual Behavior ,Social Stigma ,Human immunodeficiency virus (HIV) ,Exploratory research ,HIV Infections ,Human sexuality ,medicine.disease_cause ,Logistic regression ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Surveys and Questionnaires ,Health care ,Humans ,Medicine ,030212 general & internal medicine ,General Nursing ,030504 nursing ,Health professionals ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Cross-Sectional Studies ,Spain ,Family medicine ,Female ,0305 other medical science ,business ,Specialist Physician - Abstract
Talking about sex with people living with HIV receives insufficient attention in health care. A cross-sectional and exploratory study describes the preferences of people living with HIV to talk about sex with specialized HIV physicians and nurses in a clinic in Barcelona (Spain). A 27-item self-administered questionnaire was used between June 2017 and May 2018. One hundred fourteen people agreed to participate. Data were analyzed using multivariate logistic regression. Most of the participants reported "never or almost never" having been asked about sex practices in visits with the HIV specialist physician (n = 65 [57.0%]) or nurse (n = 74 [64.9%]). Older participants stated that neither physicians nor nurses talked about sex during visits. Women felt that physicians hardly ever asked about their sexual practices. Men who had sex with other men indicated that their physicians always asked about their sex practices compared with heterosexuals living with HIV. Health professionals should reformulate how to talk about sex with people living with HIV to facilitate communication and provide adequate care.
- Published
- 2020
42. Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients
- Author
-
Jordi Navarro, Ignacio Santos, Juan González-García, Leire Pérez-Latorre, José Hernández-Quero, Ana Carrero, José Sanz, Enrique Ortega, Juan Berenguer, Javier Hernández Bermejo, José María Bellón, Víctor Hontañón, Luz Maria Medrano, Salvador Resino, Carmen Quereda, María Jesús Téllez, and María José Galindo
- Subjects
Male ,medicine.medical_specialty ,Hepatitis C virus ,Blood lipids ,HIV Infections ,medicine.disease_cause ,Antiviral Agents ,Gastroenterology ,chemistry.chemical_compound ,Pegylated interferon ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Endothelial dysfunction ,Prospective cohort study ,Pulse wave velocity ,Inflammation ,Framingham Risk Score ,Coinfection ,business.industry ,Ribavirin ,virus diseases ,Middle Aged ,Atherosclerosis ,medicine.disease ,Hepatitis C ,digestive system diseases ,Infectious Diseases ,chemistry ,Cardiovascular Diseases ,Female ,business ,Biomarkers ,medicine.drug - Abstract
BACKGROUND To assess the effects of eradication of hepatitis C virus (HCV) on cardiovascular risk (CVR) and preclinical atherosclerosis in HIV/HCV-coinfected patients. SETTING Prospective cohort study. METHODS We assessed serum lipids, 10-year Framingham CVR scores, pulse wave velocity, carotid intima-media thickness, and biomarkers of inflammation and endothelial dysfunction (BMKs) at baseline and 96 weeks (wk) after initiation of anti-HCV therapy (Rx) in HIV/HCV-coinfected patients. RESULTS A total of 237 patients were included. Anti-HCV therapy comprised pegylated interferon and ribavirin plus 1 direct-acting antiviral in 55.2%, pegylated interferon and ribavirin in 33.8%, and all-oral direct-acting antiviral in 11.0%. A total of 147 (62.0%) patients achieved sustained viral response (SVR). Median increases in low-density lipoprotein cholesterol in patients with and without SVR were 14 mg/dL and 0 mg/dL (P = 0.024), respectively. Increases in CVR categories were found in 26.9% of patients with SVR (P = 0.005 vs. baseline) and 8.1% of patients without SVR (P = 0.433). This resulted in a significant interaction between SVR and CVR over time (P < 0.001). No significant effect of SVR was observed for pulse wave velocity (P = 0.446), carotid intima-media thickness (P = 0.320), and BMKs of inflammation and endothelial dysfunction. CONCLUSIONS In coinfected patients, eradication of HCV had no effect on markers of preclinical atherosclerosis and BMKs of inflammation and endothelial dysfunction but was associated with a clinically relevant rise in serum low-density lipoprotein cholesterol. Evaluation of CVR should be an integral part of care after the cure of chronic hepatitis C in patients with HIV.
- Published
- 2020
43. Approaching psychosocial complexity in patients with cancer
- Author
-
Jorge Maté Méndez, Cristian Ochoa Arnedo, Josep Maria Borràs Andrés, Jordi Navarro, Francisco Luis Gil Moncayo, and Anna Casellas-Grau
- Subjects
Adult ,Male ,medicine.medical_specialty ,Delphi Technique ,Advisory Committees ,Psycho-oncology ,Single group ,Psychological Distress ,Medical Records ,Low complexity ,03 medical and health sciences ,0302 clinical medicine ,Emotional distress ,Neoplasms ,Adaptation, Psychological ,medicine ,Humans ,In patient ,030212 general & internal medicine ,Aged ,Aged, 80 and over ,Patient Care Team ,business.industry ,Attendance ,Cancer ,Middle Aged ,medicine.disease ,Psychotherapy ,Physical therapy ,Female ,business ,Psychosocial - Abstract
Background and aim To assess emotional distress and complexity of patients referred to the Psychosocial Committee. Material and methods A pre-post single group study was performed in a sample of oncological patients. From the 144 patients referred to the committee, 27 were attended by psychosocial specialists. The patients’ levels of emotional distress and psychosocial complexity were reviewed one month later. Results After having been attended according to the Committee’s indications, the patients showed significant decreases in emotional distress. The initial mean of 8 points on the emotional distress scale decreased to 5.81 points after having been referred to the specialist. This decline was also observed in psychosocial complexity. Before attendance, 70.4% patients showed high levels of complexity, and 7.4% showed low levels. After attendance, the percentages of patients with high levels of psychosocial complexity reduced to 48.1% and patients with low complexity increased to 22.2%. Conclusions The Committee provides an instrument to refer patients who show high levels of psychosocial complexity and require preferential and multidisciplinary attention. The Committee optimizes resources due to its efficiency in resolving complex cases.
- Published
- 2020
44. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study
- Author
-
Daniel K, Nomah, Juliana, Reyes-Urueña, Yesika, Díaz, Sergio, Moreno, Jordi, Aceiton, Andreu, Bruguera, Rosa M, Vivanco-Hidalgo, Jordi, Casabona, Pere, Domingo, Jordi, Navarro, Arkaitz, Imaz, Elisabet, Deig, Gemma, Navarro, Josep M, Llibre, Jose M, Miro, and Juanse, Hernández
- Subjects
Pharmacology ,Microbiology (medical) ,Anti-HIV Agents ,SARS-CoV-2 ,COVID-19 ,HIV Infections ,Infectious Diseases ,COVID-19 Testing ,Lamivudine ,Emtricitabine ,Humans ,Pharmacology (medical) ,Prospective Studies ,Propensity Score ,Tenofovir - Abstract
Background Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting. Objectives We evaluated the effect of tenofovir as either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) against SARS-CoV-2 infection and associated clinical outcomes among people living with HIV (PLWH). Methods We conducted a propensity score-matched analysis in the prospective PISCIS cohort of PLWH (n = 14 978) in Catalonia, Spain. We used adjusted Cox regression models to assess the association between tenofovir and SARS-CoV-2 outcomes. Results After propensity score-matching, SARS-CoV-2 diagnosis rates were similar in TAF/FTC versus ABC/3TC recipients (11.6% versus 12.5%, P = 0.256); lower among TDF/FTC versus ABC/3TC recipients (9.6% versus 12.8%, P = 0.021); and lower among TDF/FTC versus TAF/FTC recipients (9.6% versus 12.1%, P = 0.012). In well-adjusted logistic regression models, TAF/FTC was no longer associated with reduced SARS-CoV-2 diagnosis [adjusted odds ratio (aOR) 0.90; 95% confidence interval (CI), 0.78–1.04] or hospitalization (aOR 0.93; 95% CI, 0.60–1.43). When compared with ABC/3TC, TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60–1.04) or hospitalization (aOR 0.51; 95% CI, 0.15–1.70). TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60–1.04) or associated hospitalization (aOR 0.33; 95% CI, 0.10–1.07) compared with TAF/FTC. Conclusions TAF/FTC or TDF/FTC were not associated with reduced SARS-CoV-2 diagnosis rates or associated hospitalizations among PLWH. TDF/FTC users had baseline characteristics intrinsically associated with more benign SARS-CoV-2 infection outcomes. Tenofovir exposure should not modify any preventive or therapeutic SARS-CoV-2 infection management.
- Published
- 2022
45. Induction of Resident Memory CD8 T Cell Phenotypes to Eliminate the HIV Reservoir
- Author
-
Sebastián G. Kuguel, Núria Massana, Cristina Mancebo, Jon Cantero-Pérez, Marina Suppi, Judith Grau-Expósito, Nerea Sánchez-Gaona, Josep Castellví, Laura Mañalich-Barrachina, Cristina Centeno-Mediavilla, Jordi Navarro, Adrià Curran, Vicenç Falcó, Maria J. Buzon, and Meritxell Genescà
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
46. Sexual behavior and drug use impact in gay, bisexual, and other men who have sex with men
- Author
-
Jorge N. García-Pérez, Esperanza Cañas-Ruano, Jordi Navarro, Berta Raventós, Luis López, Claudia Broto, Maider Arando, María Jesús Barberá, Vicente Descalzo, Paula Suanzes, Joaquín Burgos, Adrià Curran, and Vicenç Falcó
- Subjects
General Medicine - Abstract
The emergence of chemsex has raised several concerns about gay, bisexual, and other men who have sex with men's (GBMSM) health. In this study we aim to analyze illicit drugs and chemsex use, sexual behavior and sexually transmitted infections (STI) in GBMSM who attended to a sexual health clinic and to explore any potential association between drug use and STI.We conducted an observational study between January and June 2019 among GBMSM population attending to a STI clinic in Barcelona, Spain. An anonymous self-administered questionnaire was given consecutively to all participants older than 18 years who accepted to participate.A total of 514 GBMSM (median age of 34 years-old) were included. The median number of sexual partners in the last year was 20. Seventy-one percent did not use condoms consistently for receptive anal intercourse. Drug abuse prevalence in the preceding year was 64.2%, and 26.5% of the individuals practiced chemsex. Gamma-hydroxibutyrate/gammabutyrolactone, poppers and methamphetamine were the most common drugs in chemsex. Chemsex was associated to group sex (OR 9.8 [95 CI: 4-24]), HIV infection (OR 2.5 [95 CI: 1.1-5.8]), taking pre-exposure prophylaxis (OR 3.2 [95 CI: 1.5-7.1]), developing gonorrhea (OR 3.7 [95 CI: 1.5-8.8]) or syphilis (OR 6.7 [95 CI: 2.4-18.7]).The prevalence of drug use and chemsex was high among GBMSM in Barcelona. Chemsex was associated with group sex, taking PrEP, and contracting syphilis, gonorrhea, and HIV.
- Published
- 2021
47. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
- Author
-
Emili Letang, Lorena de la Mora, Sergio Moreno, Montse Laguno, Cristina Cortés, Paula Suanzes, Helem Haydee Vilchez, Esteban Martínez, Jordi Casabona, María Martínez-Rebollar, Francisco Homar, Ingrid Vilaró, Hernando Knobel, María Leyes, Marina Martínez, Alexy Inciarte, Antoni Jou, Jorge Palacio, Pilar Barrufet, Rocio Sola, Elena Leon, Isabel Mur, Felipe García, Angels Jaén, Àngels Masabeu, Elisa de Lazzari, Roser Font, Jose Carlos Rubia, Patrícia Sorní, Bibiana Morell, Ana Silva, José Luis Santiago Blanco, Adrià Curran, Thaïs Comella, Vicenç Falcó, Iván Chivite, Lluís Force, Anna Esteve, Mireia Cairó, Joaquim Peraire, Francesc Vidal, Francisco Fanjul, Berta Torres, Laia Arbones, Maria Saumoy, Josep Vilà, Jordi Aceiton, Guillem Fernandez, Ainoa Ugarte, Joaquín Burgos, David Dalmau, Maria Angels Ribas, Carmen Cifuentes, Josep Mallolas, Lucía Rodríguez, Rosa Maria Vivanco-Hidalgo, Pere Domingo, Eva González, Andreu Bruguera, Elisabet Deig, Consuleo Viladés, Josep M. Llibre, Lorna Leal, Juan Ambrosioni, Montserrat Vargas, Anna Martí, Arkaitz Imaz, Yesika Díaz, Marta Navarro, Aroa Villoslada, Antoni Campins, Freya Gargoulas, Manel Cervantes, Esteve Muntada, Melchor Riera, Sofia Scévola, Javier Murillas, Daniel Podzamczer, Toni Vanrell, Xavier Martinez-Lacas, Jordi Navarro, Antoni Payeras, Sonia Calzado, Maria Gracia Mateo, Elena Chamarro, Leire Berrocal, Ana González-Cordón, Maria Luisa Martin, Juliana Reyes-Urueña, Marta Molero, M. José Amengual, Maribel Tamayo, José M. Miró, Daniel Kwakye Nomah, Amat-Joaquim Orti, Jose Vicente Fernández-Montero, Maria del Mar Gutierrez, Gemma Navarro, Lizza Macorigh, María Peñaranda, and Nadia Abdulghani
- Subjects
Adult ,Male ,medicine.medical_specialty ,COVID-19 Vaccines ,Epidemiology ,Immunology ,HIV Infections ,Severity of Illness Index ,Men who have sex with men ,Cohort Studies ,COVID-19 Testing ,Virology ,Intensive care ,Internal medicine ,Medicine ,Humans ,Immunologic Factors ,Survival analysis ,Aged ,Retrospective Studies ,Asphyxia ,Aged, 80 and over ,business.industry ,Proportional hazards model ,SARS-CoV-2 ,Hazard ratio ,COVID-19 ,Retrospective cohort study ,Articles ,Middle Aged ,Infectious Diseases ,Socioeconomic Factors ,Spain ,Immunoglobulin G ,Cohort ,Female ,medicine.symptom ,business - Abstract
Summary Background Factors affecting outcomes of SARS-CoV-2 infection in people living with HIV are unclear. We assessed the factors associated with SARS-CoV-2 diagnosis and severe outcomes among people living with HIV. Methods We did a retrospective cohort study using data from the PISCIS cohort of people with HIV in Catalonia (Spain) between March 1 and Dec 15, 2020. We linked PISCIS data with integrated health-care, clinical, and surveillance registries through the Public Data Analysis for Health Research and Innovation Program of Catalonia (PADRIS) to obtain data on SARS-CoV-2 diagnosis, chronic comorbidities, as well as clinical and mortality outcomes. Participants were aged at least 16 years in care at 16 hospitals in Catalonia. Factors associated with SARS-CoV-2 diagnoses and severe outcomes were assessed using univariable and multivariable Cox regression models. We estimated the effect of immunosuppression on severe outcomes (hospital admission for >24 h with dyspnoea, tachypnoea, hypoxaemia, asphyxia, or hyperventilation; or death) using Kaplan-Meier survival analysis. Findings We linked 20 847 (72·8%) of 28 666 participants in the PISCIS cohort with PADRIS data; 13 142 people had HIV. 749 (5·7%) people with HIV were diagnosed with SARS-CoV-2: their median age was 43·5 years (IQR 37·0–52·7), 131 (17·5%) were female, and 618 (82·5%) were male. 103 people with HIV (13·8%) were hospitalised, seven (0·9%) admitted to intensive care, and 13 (1·7%) died. SARS-CoV-2 diagnosis was more common among migrants (adjusted hazard ratio 1·55, 95% CI 1·31–1·83), men who have sex with men (1·42, 1·09–1·86), and those with four or more chronic comorbidities (1·46, 1·09–1·97). Age at least 75 years (5·2, 1·8–15·3), non-Spanish origin (2·1, 1·3–3·4), and neuropsychiatric (1·69, 1·07–2·69), autoimmune disease (1·92, 1·14–3·23), respiratory disease (1·84, 1·09–3·09), and metabolic disease (2·59, 1·59–4·23) chronic comorbidities were associated with increased risk of severe outcomes. A Kaplan-Meier estimator showed differences in the risk of severe outcomes according to CD4 cell count in patients with detectable HIV RNA (p=0·039) but no differences were observed in patients with undetectable HIV RNA (p=0·15). Interpretation People living with HIV with detectable HIV viraemia, chronic comorbidities, and some subpopulations could be at increased risk of severe outcomes from COVID-19. These groups should be prioritised in clinical management and SARS-CoV-2 vaccination programmes. Funding Fundacio "la Caixa". Translations For the Catalan, Spanish and Russian translations of the Summary see Supplementary Materials section.
- Published
- 2021
48. A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols as an adjunct to hemostasis compared with manual compression in vascular surgery
- Author
-
Jordi Navarro-Puerto, Brajesh K. Lal, Alvaro M. Segura-Vasi, Waleska Henriquez, Igor Sonkin, Joseph Griffin, Lajos Mátyás, Kecia Courtney, Henry Li, Harold S. Minkowitz, Alik Farber, Daniel M. Ihnat, Stuart M. Greenstein, Susan Beck, Sibu P. Saha, Jaume Ayguasanosa, Ali Amin, John H. Matsuura, John R. Hoch, Junliang Chen, Ivan Katelnitskiy, Julia Ibañez, Mohammad H. Eslami, Anil Paramesh, Dragoslav Nenezic, Yanmei Zhang, Vladan Popović, Carmen Soucheiron, Andrey Karpenko, Gladis Barrera, Carrie Hames, Albert Yurvati, German Sokurenko, Valerie Lloyd, Jiang Lin, Nam T. Tran, Ravi R. Rajani, Satish C. Muluk, Deborah Covington, Benjamin S. Brooke, Holjencsik Tamás, Gábor Menyhei, Romà Casamiquela, and Paul W. White
- Subjects
Adult ,Male ,medicine.medical_specialty ,Blood Loss, Surgical ,Vital signs ,Fibrin Tissue Adhesive ,030204 cardiovascular system & hematology ,Fibrin ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Pressure ,Humans ,Medicine ,Single-Blind Method ,Prospective Studies ,030212 general & internal medicine ,Adverse effect ,Aged ,Aged, 80 and over ,Hemostatic Agent ,biology ,business.industry ,Middle Aged ,Vascular surgery ,Hemostasis, Surgical ,Adjunct ,Surgery ,Clinical trial ,Treatment Outcome ,Hemostasis ,biology.protein ,Female ,Cardiology and Cardiovascular Medicine ,business ,Vascular Surgical Procedures - Abstract
New formulations and applications of hemostatic adjuncts such as fibrin sealant (FS) to support local hemostasis and sutures continue to be developed. In a pivotal, confirmatory, controlled, prospective, single-blinded, randomized, multicenter phase III clinical trial, the efficacy and safety of FS Grifols during vascular surgeries were evaluated.Patients undergoing a nonemergency, open, peripheral vascular surgical procedure with moderate arterial bleeding were recruited. In an initial preliminary part of the study, all patients were treated with FS Grifols. In a subsequent primary part, patients were randomized (2:1) to FS Grifols or manual compression (MC). The primary efficacy end point was the proportion of the primary part patients achieving hemostasis by 4 minutes after the start of treatment. Cumulative proportion and time to hemostasis were secondary efficacy end points. Safety end points (in pooled preliminary and primary parts) included adverse events (AEs), vital signs, physical assessments, clinical laboratory tests, viral markers, and immunogenicity.The primary efficacy end point was met by 76.1% of patients (83/109) for the FS Grifols group versus 22.8% of patients (13/57) for the MC group (P .001). The cumulative proportion of patients at 5, 7, and 10 minutes was 80.7%, 84.4%, and 88.1%, respectively, in the FS Grifols treatment group, and 28.1%, 35.1%, and 45.6% in the MC treatment group (P .001). The median time to hemostasis was shorter in the FS Grifols group (4 minutes vs ≥10 minutes in the MC group; P .001). The nature of AEs reported were those expected in the study patient profile. The percentage of patients experiencing treatment-emergent AEs were similar in both the FS Grifols (pooled n = 59 + 109) and MC groups (81.0% and 77.2%, respectively), most recurrent being procedural pain (34.5% and 36.8%, respectively) and pyrexia (11.3% and 10.5%, respectively).FS Grifols was superior in efficacy and similar in safety to MC as an adjunct local hemostatic agent in patients undergoing open vascular surgeries.
- Published
- 2019
49. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice
- Author
-
Núria Pérez-Álvarez, Bonaventura Clotet, Mario F Ampuero, Pablo Pelaez, Roger Paredes, Adrian Curran, José R. Santos, José Moltó, and Jordi Navarro-Mercade
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Darunavir+Ritonavir ,Anti-HIV Agents ,Darunavir/Cobicistat ,Immunology ,HIV Infections ,PI monotherapy ,DRV/r ,03 medical and health sciences ,0302 clinical medicine ,Virology ,Internal medicine ,Antiretroviral treatment ,medicine ,Humans ,Routine clinical practice ,Treatment Failure ,030212 general & internal medicine ,Practice Patterns, Physicians' ,Darunavir ,Retrospective Studies ,DRV/c ,Ritonavir ,Drug Substitution ,business.industry ,Cobicistat ,HIV Protease Inhibitors ,Middle Aged ,Viral Load ,routine clinical practice ,030104 developmental biology ,Infectious Diseases ,HIV-1 ,RNA, Viral ,Female ,simplification strategy ,business ,medicine.drug - Abstract
Our aim was to evaluate the effectiveness and safety of darunavir/cobicistat (DRV/c) monotherapy as an antiretroviral treatment simplification strategy in HIV-infected patients already on suppressive darunavir/ritonavir (DRV/r) monotherapy in routine clinical practice. We conducted a retrospective multicenter study including all adult patients switched from DRV/r monotherapy to DRV/c monotherapy while HIV-1 RNA was = 50 copies/mL or any change in the regimen after a single determination with HIV-1 RNA >= 50 copies/mL. Changes in renal function parameters and lipid profile were also evaluated. Factors associated with VF were analyzed using Cox regression. In this study, 173 subjects were included. The median (interquartile range) time of follow-up was 58 (50-67) weeks. Overall, 90% of patients remained free of TF during follow-up. Ten (6%) patients discontinued DRV/c monotherapy for nonvirological reasons and eight (5%) developed VF. No DRV-related mutations were identified in patients with VF. A decrease in triglyceride levels (p = .006) and estimated glomerular filtration rate (p = .005) were observed during follow-up. The presence of blips and CD4+ nadir
- Published
- 2019
50. Safety and efficacy of intravenous immunoglobulin (Flebogamma® 10% DIF) in patients with immune thrombocytopenic purpura
- Author
-
Chirag Shah, Paul Pinciaro, Maria Esperança Aragonés, Karen Rucker, Gladis Barrera, Jaume Ayguasanosa, Sharat Damodar, Vijay Ramanan, Chieh-Lin 'Kathy' Fu, Shashikant Apte, Giraldo Kato, Marcela Torres, Joseph M John, Jordi Navarro-Puerto, and Cecil Ross
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Immunology ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Immunology and Allergy ,In patient ,Platelet ,Adverse effect ,End point ,biology ,business.industry ,medicine.disease ,Thrombocytopenic purpura ,Flebogamma ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,biology.protein ,Antibody ,business - Abstract
Aim: To evaluate the safety and efficacy of 10% intravenous immunoglobulin (IVIG; Flebogamma® 10% DIF) in individuals with chronic immune thrombocytopenic purpura (ITP). Patients & methods: Patients aged 3–70 years, diagnosed with chronic ITP, received 1 g/kg IVIG over two consecutive days. Results: 64 evaluable patients (51 adults, 13 children) with chronic ITP received IVIG. The primary efficacy end point (increased platelet counts from ≤20 × 109/l to ≥50 × 109/l by day 8) was achieved by 81.3% of patients; mean time to response was 1.7 days (all responders). Adverse events, mostly mild or moderate, were reported in 59 patients (92.2%). Conclusion: Flebogamma® 10% DIF administered over two consecutive days was safe and effective in adults and children with chronic ITP.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.